The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II study of olaparib (without ADT) in men with high-risk biochemically-recurrent prostate cancer following prostatectomy, with integrated biomarker analysis.
 
Benjamin A. Teply
Stock and Other Ownership Interests - BIND Therapeutics; Selecta Biosciences
Research Funding - AstraZeneca (Inst)
Patents, Royalties, Other Intellectual Property - MIT
 
Hao Wang
No Relationships to Disclose
 
Rana Sullivan
No Relationships to Disclose
 
Serina King
Consulting or Advisory Role - Abbvie
 
Catherine Handy
Research Funding - Conquer Cancer Foundation/Bristol-Myyers Squibb
 
Tamara L. Lotan
No Relationships to Disclose
 
Emmanuel S. Antonarakis
Honoraria - Astellas Pharma; Dendreon; ESSA; Janssen Biotech; Medivation; Sanofi
Consulting or Advisory Role - Astellas Pharma; Dendreon; ESSA; Janssen Biotech; Medivation; Sanofi
Research Funding - Aragon Pharmaceuticals (Inst); Astellas Pharma (Inst); Dendreon (Inst); Exelixis (Inst); Genentech (Inst); Janssen Biotech (Inst); Johnson & Johnson (Inst); Millennium (Inst); Novartis (Inst); Sanofi (Inst); Tokai Pharmaceuticals (Inst)
Travel, Accommodations, Expenses - Dendreon; Medivation; Sanofi